Roche gains rights to Oryzon's cancer-drug candidate

04/8/2014 | Reuters

Oryzon Genomics granted Roche Holding the rights to its experimental drug ORY-1001, which is in early-stage trials for acute myeloid leukemia. The deal entitles Oryzon to $21 million worth of upfront and near-term milestone fees plus more than $500 million if other targets are hit, in addition to sales royalties. The deal includes the collaborative development of LSD1 inhibitors at Roche's research facility in New York.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL